Blue Note Therapeutics and OncoHealth have partnered to deliver oncology-specific mental health care.
OncoHealth, Blue Note Therapeutics partner to provide a digital therapeutic for cancer-related anxiety and depression
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Unquestionably, a child’s cancer diagnosis weighs heavily on the parents’ minds. But now, an analysis of nearly 30,000 U.S. families has quantified how often parents of children with cancer use mental health services.
Shasqi, Inc. and Johnson & Johnson Enterprise Innovation Inc. have expanded their ongoing research collaboration.
Pierre Fabre Laboratories and Vernalis, a fully owned subsidiary of HitGen Inc., established a long-term partnership to identify pre-clinical candidates against oncology targets.
The Association of Community Cancer Centers—with its partners, the Association of Oncology Social Work and the American Psychosocial Oncology Society—is calling for sweeping improvements to mental health care services and support for patients, caregivers, and mental health care professionals experiencing psychological distress.
Depression and anxiety are thought to increase a person’s risk of developing cancer, but research results have been inconclusive. In an analysis of multiple studies from the Netherlands, the United Kingdom, Norway, and Canada, investigators found that depression and anxiety are not linked to higher risks for most types of cancer among this population. The analysis is published in Cancer.
A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.